Drug details
Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf injection)
type of Antineoplastics, Anti-HER2
Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) is a combination of HER2/neu receptor antagonists and an endoglycosidase indicated for use in combination with chemotherapy as neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer; and adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence Phesgo is also indicated for use in combination with docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.
This drug may have the following side effects:
- nausea,
- rash,
- vomiting,
- diarrhea,
- constipation,
- joint pain,
- fatigue,
- weakness,
- hair loss,
- decreased appetite, and
- muscle pain
- low white blood cell count (neutropenia),
- insomnia
- anemia,
- numbness and tingling of extremities,
The following drugs are related to Phesgo, either as a replacement or used together:
- Verzenio (abemaciclib tablets)
- Kadcyla (ado-trastuzumab emtansine injection for iv use)
- Afinitor (everolimus tablets)
- Afinitor Disperz (everolimus tablets)
- Piqray (alpelisib tablets)
- Arimidex (anastrozole)
- Orserdu (elacestrant tablets)
- Faslodex (fulvestrant)
- Herceptin (trastuzumab)
- Herceptin Hylecta (trastuzumab and hyaluronidase-oysk injection, for subcutaneous use)
- Ixempra (ixabepilone)
- Kisqali (ribociclib tablets)
- Kisqali FeMara Co-Pack (ribociclib and letrozole tablets)
- Tykerb (lapatinib)
- Lynparza (olaparib capsules for oral administration)
- Margenza (margetuximab-cmkb injection, for intravenous use)
- Perjeta (pertuzumab)
- Tukysa (tucatinib tablets)